EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats

Simon Kloock, Niklas Haerting, Gloria Herzog, Marie Oertel, Niklas Geiger iD, Andreas Geier, Vasco Sequeira iD, Alexander Nickel, Michael Kohlhaas, Martin Fassnacht iD, Ulrich Dischinger

Nutrients · 2024

DOI: 10.3390/nu16060904 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Simon Kloock und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital Wuerzburg, University of Wuerzburg, 97080 Wuerzburg, Ger…. Hauptthemen laut MEDLINE: Receptors, Neuropeptide Y, Fatty Liver, Glucagon-Like Peptides, Benzamides. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IZKF Würzburg, Deutsche Forschungsgemeinschaft, Open Access Publication Fund of the University of Wuerzburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Modulators of the Neuropeptide Y (NPY) system are involved in energy metabolism, but the effect of NPY receptor antagonists on metabolic-dysfunction-associated steatotic liver disease (MASLD), a common obesity-related comorbidity, are largely unknown. In this study, we report on the effects of antagonists of the NPY-2 receptor (Y2R) in comparison with empagliflozin and semaglutide, substances that are known to be beneficial in MASLD. (2)

Methods

Diet-induced obese (DIO) male Wistar rats were randomized into the following treatment groups: empagliflozin, semaglutide ± PYY3-36, the Y2R antagonists JNJ 31020028 and a food-restricted group, as well as a control group. After a treatment period of 8 weeks, livers were weighed and histologically evaluated. QrtPCR was performed to investigate liver inflammation and de novo lipogenesis (in liver and adipose tissue). Serum samples were analysed for metabolic parameters. (3)

Results

Semaglutide + PYY3-36 led to significant weight loss, reduced liver steatosis (p = 0.05), and decreased inflammation, insulin resistance, and leptin levels. JNJ-31020028 prevented steatosis (p = 0.03) without significant weight loss. Hepatic downregulation of de novo lipogenesis-regulating genes (SREBP1 and MLXIPL) was observed in JNJ-31020028-treated rats (p ≤ 0.0001). Food restriction also resulted in significantly reduced weight, steatosis, and hepatic de novo lipogenesis. (4)

Conclusions

Body weight reduction (e.g., by food restriction or drugs like semaglutide ± PYY3-36) is effective in improving liver steatosis in DIO rats. Remarkably, the body-weight-neutral Y2R antagonists may be effective in preventing liver steatosis through a reduction in de novo lipogenesis, making this drug class a candidate for the treatment of (early) MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Neuropeptide YFatty LiverGlucagon-Like PeptidesBenzamidesPiperazinesGlucosidesBenzhydryl CompoundsRatsMaleAnimalsRats, WistarObesityDietWeight LossInflammationSemaglutide

Stichwörter der Autor:innen

DIO ratsMASHMASLDPYYdiabetesneuropeptide Yobesitysemaglutide

Substanzen

Receptors, Neuropeptide YGlucagon-Like PeptidesBenzamidesPiperazinesGlucosidesBenzhydryl CompoundsSemaglutideJNJ-31020028empagliflozin

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital Wuerzburg, University of Wuerzburg, 97080 Wuerzburg, Germany.
  • Institute of Pathology, University of Wuerzburg, 97070 Wuerzburg, Germany.
  • Department of Internal Medicine, Division of Hepatology, University Hospital Wuerzburg, University of Wuerzburg, 97080 Wuerzburg, Germany.
  • Comprehensive Heart Failure Center, University Hospital Wuerzburg, University of Wuerzburg, 97080 Wuerzburg, Germany.

ORCID-Profile: Niklas Geiger, Vasco Sequeira, Martin Fassnacht

Förderung

  • IZKF Würzburg
  • Deutsche Forschungsgemeinschaft
  • Open Access Publication Fund of the University of Wuerzburg

Zitieren

APA

Kloock, S., Haerting, N., Herzog, G., Oertel, M., Geiger, N., Geier, A., Sequeira, V., Nickel, A., Kohlhaas, M., Fassnacht, M., & Dischinger, U. (2024). Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats. Nutrients. https://doi.org/10.3390/nu16060904

Vancouver

Kloock S, Haerting N, Herzog G, Oertel M, Geiger N, Geier A, et al. Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats. Nutrients. 2024. doi:10.3390/nu16060904

BibTeX
@article{Kloock2024,
  author = {Kloock, Simon and Haerting, Niklas and Herzog, Gloria and Oertel, Marie and Geiger, Niklas and Geier, Andreas and Sequeira, Vasco and Nickel, Alexander and Kohlhaas, Michael and Fassnacht, Martin and Dischinger, Ulrich},
  title = {Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16060904}
}
Kostenlos starten →